Articles

Scrutiny rises on Bankers Life

After the insurer's name went on Indianapolis' downtown arena, CBS News focused on how hundreds of Bankers Life’s long-term-care insurance policyholders have accused the company of having “beat them down with bureaucracy."

Read More

Pressure rises as Lilly tries squeeze play

Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.

Read More

IU doc growth slower than expected

Indiana University Health Physicians started as the Indiana Clinic three years ago with plans to employ at least 1,200 physicians by now. That hasn’t happened, but the organization said it won’t stop folding doctors into its organization.

Read More

Shareholders gives earful to BASI execs

For the first time in three years, Bioanalytical Systems Inc. boosted its annual revenue. But instead of receiving congratulations, one of the company’s largest shareholders said the company’s trends are “bleak.”

Read More

Walgreen expects to lose most Express Scripts biz

Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.

Read More

Lilly losing dominance in diabetes treatment

Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.

Read More

Filing: Roche considered leaving Indy

It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.

Read More

Q&A

Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.

Read More